All studies
AuthorisedTherapeutic confirmatory (Phase III)Interventional

Model-informed precision dosing for linezolid: a randomized clinical trial

Linezolid is a strong antibiotic used to treat serious bacterial infections, such as severe pneumonia or deep skin infections, in hospital intensive care units. Normally, everyone gets a standard dose. However, people who are very unwell often process medicines differently, meaning the standard dose can sometimes be too low to fight the germ or too high and cause side effects. This clinical trial is testing 'precision dosing'. This approach uses regular blood checks and computer programmes to calculate the exact amount of medicine each patient needs. Researchers want to see if this method reliably keeps linezolid at the safest and most effective level in the blood by day seven of treatment. The goal is to improve infection recovery while lowering the risk of side effects like low blood platelet counts.

At a glance

Status
Authorised
Phase
Therapeutic confirmatory (Phase III)
Sponsor
University Medical Center Hamburg-Eppendorf
Enrolment target
30
Start
13 Jul 2026

What is this study about?

When people become critically ill with serious infections such as pneumonia or deep skin infections, they often need treatment in an intensive care unit (ICU). Doctors frequently use a powerful antibiotic called linezolid to fight these difficult bacterial bugs. In usual NHS care, patients are given a standard fixed dose of the drug twice a day.

However, a patient's body in intensive care can change rapidly. Organs like the kidneys and liver may work differently from day to day, altering how fast medicine is cleared from the blood. If antibiotic levels fall too low, the infection may not clear and bacteria can become resistant. If levels rise too high, linezolid can cause unwanted side effects, such as a drop in platelets (the cells that help blood clot) or a build-up of acid in the blood.

This trial compares standard dosing against a personalised approach called model-informed precision dosing. In the personalised group, doctors measure the amount of linezolid in the blood and use computer software to tailor future doses to the patient's individual needs. Researchers will check blood levels on day seven and day thirteen to see which approach works best.

By taking part, patients help doctors discover whether personalised dosing helps people recover faster, spends less time in intensive care, and avoids common antibiotic side effects.

Key takeaways

  • Testing personalised, computer-guided antibiotic doses against standard doses in the ICU.
  • Aims to treat severe pneumonia and skin infections while reducing medicine side effects.
  • Focuses on keeping linezolid levels in a safe, effective target range by day seven.
  • Open to adults aged 18 and older receiving linezolid in intensive care.
  • Monitoring uses routine ICU blood tests and does not interrupt essential medical care.

Who may be eligible?

This trial is for adults aged 18 and over who are currently being treated in an intensive care unit (ICU). To join, the patient must have a serious bacterial infection—such as severe pneumonia or a deep skin and tissue infection—that requires treatment with the antibiotic linezolid.

Because patients in intensive care are often very sick or sedated, doctors and research nurses will carefully check their medical records to confirm that linezolid is the right choice for them. Both men and women can take part.

People who cannot safely receive linezolid, or those who have specific medical conditions that clash with the trial requirements, will not be able to join. The hospital care team will check all safety criteria before enrolling anyone.

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

  1. The patient is aged 18 or older.
  2. The patient is currently admitted to an intensive care unit (ICU).
  3. The patient has a confirmed or suspected severe bacterial infection (such as pneumonia or skin infection).
  4. The medical team has decided that treatment with linezolid is necessary.
Answer every question to see your result.

What does participation involve?

Taking part takes place entirely while the patient is being treated in the intensive care unit. Patients are placed into one of two groups: one receives standard linezolid doses, and the other receives doses adjusted by computer modelling based on blood test results. Blood samples are taken at set times—particularly on day seven and day thirteen—to check antibiotic levels, blood cell counts, and liver and kidney health. Small swabs may also be taken to check for bacteria. Because blood tests and monitoring are already part of normal intensive care, few extra needle pricks are needed. The study lasts for the duration of the linezolid course, usually up to two weeks, with standard hospital follow-up.

Potential risks and benefits

A potential benefit is that computer-tailored dosing may keep the antibiotic at an ideal level, helping clear the infection effectively while minimising complications. However, there is no guarantee of direct personal benefit. The risks are mainly the known side effects of linezolid, which include temporary drops in blood platelets, nausea, or nerve tingling, though the trial aims to reduce these problems through careful monitoring. Joining is entirely voluntary. If a patient or their family decides to stop taking part, normal intensive care treatment continues without any change.

Locations (1)

Some site locations are approximate. We're improving this — please verify with the trial team before travelling.
  • —
    Unverified
    Germany

Common questions

What is linezolid?

Linezolid is a strong antibiotic used in hospitals to treat serious bacterial infections that do not respond to simpler medicines.

Why change the dose instead of giving everyone the same amount?

People in intensive care process medicines at very different speeds. Personalising the dose helps ensure there is enough medicine to kill bacteria without causing toxic levels.

What happens if a patient is too unwell to give consent?

In intensive care, doctors follow strict legal rules. They will speak with a family member, partner, or nominated representative to ask for their agreement before including the patient.

Will taking part cause extra pain or blood tests?

ICU patients usually have special lines already in place for blood tests, so study blood samples can almost always be taken without extra needle pricks.

Can a patient leave the study once it starts?

Yes. Patients or their representatives can withdraw at any time. Doing so will not affect the quality of their NHS medical care.

How to find out more

Always speak to your GP or specialist before deciding to take part in a study.

Discussion

Community discussion

Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.